RINGPU(SZ:300119) Huaxin Securities·2026-02-25 07:05Investment Rating - The report maintains a "Buy" rating for the pet vaccine industry, indicating a positive outlook for investment opportunities in this sector [10]. Core Insights - The rise of domestic brands in the pet vaccine industry follows a clear path of development, transitioning from initial breakthroughs to deep market penetration and ultimately to ecosystem establishment [5][17]. - The domestic cat trivalent vaccine market has seen a significant shift, with domestic brands capturing 84.53% of the market share by 2025, marking a substantial decline in the dominance of imported brands [48][54]. - The pet drug market is characterized by a dual structure, with international giants dominating the high-end market while domestic brands focus on the mid-to-low end, leveraging price advantages [8][60]. Summary by Sections 1. Domestic Replacement Paradigm Deconstruction - The growth of domestic brands is structured in three phases: 0-1 breakthrough, 1-10 deepening, and 10-100 leap [17][18]. - Successful examples from other industries, such as pet food and coffee, illustrate the effectiveness of this model in achieving market penetration and brand trust [4][26]. 2. Pet Vaccine Industry - The cat trivalent vaccine market has transitioned from a monopoly by Zoetis to a competitive landscape with multiple domestic players, achieving a market share of 80.7% [46][48]. - Domestic vaccines have advantages in matching local viral strains and improving safety through advanced production standards [57]. 3. Key Companies and Profit Forecasts - The report highlights the performance of key companies, such as Reap Bio, with projected earnings per share (EPS) increasing from 0.65 in 2024 to 1.08 in 2026, reflecting strong growth potential [12]. 4. Industry Rating and Investment Strategy - The report emphasizes the expanding demand in the pet market and the promising future of the pet vaccine sector, reinforcing the "Buy" rating [10].